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1. Introduction 
It has been known for many years that concana- 
valin A, the jack bean phytohemagglutinin, preci- 
pitates with polysaccharides [1 ]. However, only 
since the paper by Goldstein et al. [2] in 1965, has 
the concanavalin A-polysaccharide system been 
studied in detail. Branched glucans, fructans and 
mannans interact with concanavalin A through 
their non-reducing terminii [3]. One feature of con- 
canavalin A-neutral polysaccharide complexes i
their stability in wide concentrations of salts [4], 
thereby negating electrostatic effects in the inter- 
action. 
A report by Doyle et al. [5] demonstrated that 
concanavalin A would interact with heparin and 
showed that complex formation could be inhibited 
by either sodium chloride or D-glucose, the latter 
being a known inhibitor of concanavalin A-neutral 
polysaccharide interactions. Previously, Cifonelli 
et al. [6] reported an interaction between concana- 
valin A and heparin. More recently, DiFerrante and 
Hrgovcic [7] could find no evidence for complex 
formation between the phytohemagglutinin and 
heparin using the conditions of Doyle et al. [5], 
These findings led us to re-examine the interaction 
between concanavalin A and heparin. In this report, 
it is shown that concanavalin A forms precipitin- 
like complexes with heparin and that the interaction 
is pH, salt and sugar sensitive. 
* To whom correspondence should be addressed. 
2. Materials and methods 
Concanavalin A used in this study was prepared 
from finely ground jack beans by the standard 
Agrawal and Goldstein [8] procedure. Following 
initial purification, the concanavalin A was re- 
cycled to insure its purity. 
Oyster glycogen was purchased from Nutritional 
Biochemicals, Cleveland, Ohio. Methyl a-D-manno- 
pyranoside was purchased from Calbiochem, Los 
Angeles, Calif. Three heparin samples were used in 
this study: A) Heparin, Na salt, B grade, Calbiochem. 
Analyses howed that this sample contained 44% 
uronic acid (as glucuronic acid equivalents [9], 
6.7% hexose (anthrone), 1.95% nitrogen [10], 10.0% 
sulfur [11] and 16.0% ash. B) Heparin, Na salt, 
grade I, Sigma, St. Louis, Mo. This preparation con- 
tained 42% uronic acid, 7.3% hexose, 1.85% nitro- 
gen, 13.0% sulfur and 16.7% ash. C) Heparin, ki 
salt, grade IV, Sigma. Analyses of this sample gave 
42% uronic acid, 6.8% hexose, 2.05% nitrogen, 13.0% 
sulfur and 10.1% ash. Within experimental error, 
the different heparin preparations gave identical re- 
sults. Therefore, for purposes of brevity, only the 
data for the heparin-Li salt will be discussed. 
The following procedure was followed to study 
concanavalin A-heparin precipitate formation: con- 
canavalin A (1 ml at 2.0 mg/ml) and heparin (1.0 ml 
at 0.032-4.0 mg/ml) in deionized water were added 
to 2.0 ml of 0.10 M buffer solution. After 20 rain, 
the turbidities were measured in 0.5 inch rounded 
cuvettes in a Bausch and Lomb Spectronic 20 
colorimeter at 420 rim. Buffer solutions were pre- 
pared according to Gomori [12]. Acetate buffers 
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Fig. 1. The effects of  heparin (A) and glycogen (B) concen- 
tration on precipitation with concanavalin A in 0.05 M 
acetate buffer, pH 5.4. 
were used between pH 3 and 5.6 and above pH 5.8 
phosphate buffers were employed. Hydrogen ion 
concentrations were determined immediately follow- 
ing the turbidity measurements. In the experiments 
requiring added sodium chloride or methyl a-manno- 
side, the addition was made to buffer prior to con- 
canavalin A and heparin. 
3. Results and discussion 
Because of its polyanionic haracter, heparin 
should be able to form electrostatic complexes 
with a variety of proteins. Several cases have been 
documented showing heparin-protein interactions 
[13, 14]. The concanavalin A-heparin system may 
be more complex. Concanavalin A and heparin were 
mixed at different pH values and the turbidities re- 
corded. No interaction was observed above pH 5.8. 
A pH of 5.4 gave optimum turbidity. This contrasts 
with concanavalin A-neutral polysaccharide inter- 
actions in which the pH optimum is near neutrality 
[4]. Analyses of the precipitates for uronic acid 
and protein showed that the insoluble materials 
were concanavalin A-heparin complexes. Turbidity 
was proportional to the amount of heparin and 
concanavalin A in the precipitates. 
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Fig. 2. Inhibition of the reaction between concanavalin A 
and heparin by methyl  a-D-mannopyranoside (A) and sodium 
chloride (B). 
The effect of heparin concentration is shown in 
figl 1. A classical precipitin-like reaction was ob- 
tained for each of the heparin samples in 0.05 M 
acetate buffer, pH 5.4. Based on the turbidimetric 
assay, 2.0 mg concanavalin A combined with approx. 
0.25 mg heparin at the equivalence point. In con- 
trast to heparin, the concanavalin A precipitin pro- 
f'de with glycogen is much broader (fig. 1) [15]. 
Qualitatively, the concentration dependence of
the concanavalin A-heparin complex is similar to 
that of concanavalin A-dextran complexes [2]. 
The foregoing data firmly establish that concana- 
valin A and heparin interact to form visible com- 
plexes. The question to be answered iswhether 
heparin and neutral polysaccharides bind to the 
same site(s) on the concanavalin A molecule. It is 
shown in fig. 2 that NaC1 at concentrations ap- 
proaching 0.1 M completely inhibits the concanavalin 
A-heparin interaction. This is consistent with the 
concept that the complex is mediated through ionic 
binding. If the interaction were dependent on the 
binding of sugar termini by concanavalin A, in- 
hibition should be observed when methyl a-manno- 
side is present [3]. At 0.053 M, methyl a-mannoside 
gave approx. 58% inhibition (fig. 2) Much lower con- 
centrations of methyl ct-mannoside are required to 
completely inhibit concanavalin A-neutral glucan 
interactions [3]. 
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In our earlier eport [5], 0.1 M NaC1 concentra- 
tions were used and a concanavalin A-hepar in  com- 
plex was observed. Using the same conditions, 
DiFerrante and Hrgovic [7] saw no precipitation. 
From the data presented in this paper, it is apparent 
that 0.1 M NaC1 is near the threshold concentration 
for total inhibition of visible precipitate formation 
and that slight variations in ionic strength profound- 
ly influence the interaction. Our previously used 
heparin preparation was not analyzed for ash. Com- 
mercial heparin preparations frequently contain 
salts. Thus, it is possible that contaminating salts 
would add to the inhibitory effects of exogenous 
ions. 
The fact that methyl a-mannoside is a partial 
inhibitor of the concanavalin A-hepar in  complex 
presents an interesting situation. If the complex 
were completely dependent on electrostatic forces, 
methyl a-mannoside would not be expected to 
show competitive ffects. We have shown (R.J. 
Doyle and R. Glew, unpublished results) that methyl 
a-mannoside induces a conformational change in 
concanavalin A. Thus, a ligand-induced conforma~ 
tional change in the protein may result in the mask- 
ing of ionic sites involved in the interaction with 
heparin. 
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